Nanoscope Therapeutics Inc.
Michael Marquez is currently the CFO at Nanoscope Therapeutics Inc. Prior to this role, Michael held the CFO position at TearLab Corporation from September 2015 to June 2022 and at Alcon from May 2008 to September 2015. Michael has a BBA in Accounting from The University of Texas at Austin and a Master's degree in Accounting from The University of Texas at Arlington. Michael also has experience working as an Associate at PwC from June 2005 to May 2008. Additionally, Michael has participated in executive education programs at the University of Chicago Booth School of Business and Kellogg Executive Education.
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa